Company profile
Bionano Genomics, Inc.
NASDAQ: BNGO · Healthcare · Medical - Instruments & Supplies
#511 of 1,418 Healthcare companies by revenue34th-percentile growth
EA Score
48DFH 51DQ 45GM 44SS 49
v0.1 · 65/100 weight · provisional
↑ Piotroski F, balance-sheet leverage · ↓ Altman-Z, revenue growth (YoY)
Methodology →Revenue TTM
$28.7M
Rev growth YoY (TTM)
+1.0%
Net income (FY)
-$26.4M
Employees
96
as of 2026-08-22
Market cap
$13.8M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$28.5M$28.5M2025
Net income-$26.4M-$26.4M2025
Operating income-$33.3M-$33.3M2025
Total assets$73.6M$73.6M2025
Liabilities$29.2M$29.2M2025
Equity$44.4M$44.4M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product48%
Consumable Revenue25%
Software Revenue12%
Instrument Revenue12%
Product and Service, Other3%
By geography
EMEA49%
Americas43%
Asia Pacific8%
The read
What is Bionano Genomics, Inc.’s revenue?
Bionano Genomics, Inc. booked $28.5M in FY2025 revenue, contracting 7.4% year over year — slower than 66% of Healthcare companies we track, at a -92.6% net margin.
Peers · Healthcare
IMRIS Inc.——Nanalysis Scientific Corp.59COscar Health, Inc.50DLowell Farms Inc.——American Shared Hospital Services59CImmuCell Corporation64CNeighbors
San Diego →Key facts
CEOAlbert A. Luderer
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersSan Diego, CA
ExchangeNASDAQ: BNGO
Employees96
IPO date2018-08-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.